Arcutis Biotherapeutics, Inc., a pioneer in immuno-dermatology, has announced the U.S. Food and Drug Administration’s (FDA) approval of their new drug application for ZORYVE (roflumilast) topical foam, 0.3%, aimed at treating seborrheic…
Business news around the world
Arcutis Biotherapeutics, Inc., a pioneer in immuno-dermatology, has announced the U.S. Food and Drug Administration’s (FDA) approval of their new drug application for ZORYVE (roflumilast) topical foam, 0.3%, aimed at treating seborrheic…